News
Our latest news and announcements
New project supports the development of innovative products and processes through additive manufacturing
CPI has announced a new project offering flexible access to innovation facilities and expertise in commercialising new products and processes in the additive manufacturing and coating industries.
CPI accelerates gene therapy development with robust adeno-associated virus purification system
CPI today announces the success of its CRD IUK project to develop a scalable, cost-effective purification process for adeno-associated viruses (AAVs), in partnership with Cobra Biologics and GE Healthcare Life Sciences. The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.
The Medicine Manufacturing Innovation Centre to develop platform for quicker optimisation of oral solid drug formulations
CPI and the University of Strathclyde, in strategic partnership with GSK and AstraZeneca, today announced a new platform that will enable oral solid dosage medicines to be formulated more robustly and efficiently.
Development of an In-House Cell Free Extract Process and Robotic Platform for Expression Optimisation
The advent of personalised medicine promises more efficacious treatments. However, moving away from a ‘one size fits all’ model demands new, adaptable and complex manufacturing processes for the next generation of therapeutics.
CPI and EU partners create commercialisation support for photonics
Small and Medium-sized Enterprises (SMEs) working with photonics in life sciences markets can benefit from the support offered by CPI and other European partners, as part of the Horizon 2020 project EPRISE (Empowering Photonics through Regional Innovation Strategies in Europe).
CPI optimises development of novel biotherapeutics with BioStreamline project
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, has recently disseminated the results of the £11.2 million BioStreamline project to optimise the development of novel biotherapeutics.